RxDoctor Payments Data

Laura Havrilesky, MD

Gynecologic Oncology · Durham, NCNPI 1316971526

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Intuitive Surgical. That places this record below the midpoint for gynecologic oncology clinicians in NC, where the typical reported total is $1,376.

$29in general payments, 2019–2025

Across 1 payment — averaging $28.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$29
$176,014in research payments, 2019–2025

Across 2 payments — averaging $88,007 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$176K

What the payments were for

  • Food & beverage$29100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical1$29

How this compares

$29 in reported general payments places this provider in the 5th percentile of 52 gynecologic oncology providers in North Carolina.

See all gynecologic oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$55,805
Medicare patients
169
Services billed
635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZejulaNiraparib Tosylate13$241,278
Letrozole14$157

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →